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ABSTRACT Transforming growth factor
(TGF-b) protein families are cytokines that occur as
a large number of homologous proteins. Three ma-
jor subgroups of these proteins with marked speci-
ficities for their receptors have been found—TGF-b,
activin/inhibin, and bone morphogenic protein. Al-
though structural information is available for some
members of the TGF-b family of ligands and recep-
tors, very little is known about the way these growth
factors interact with the extracellular domains of
their cell surface receptors, especially the type II
receptor. In addition, the elements that are the
determinants of binding and specificity of the li-
gands are poorly understood. The structure of the
extracellular domain of the receptor is a three-
finger fold similar to some toxin structures. Amino
acid exchanges between multiply aligned homolo-
gous sequences of type II receptors point to a resi-
due at the surface, specifically finger 1, as the deter-
minant of ligand specificity and complex formation.
The “knuckle” epitope of ligands was predicted to
be the surface that interacts with the type II recep-
tor. The residues on strands b2, b3, b7, b8 and the
loop region joining b2 and b3 and joining b7 and b8
of the ligands were identified as determinants of
binding and specificity. These results are supported
by studies on the docking of the type II receptor to
the ligand dimer–type I receptor complex. Proteins
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INTRODUCTION
The transforming growth factor b (TGF-b) family com-
prises a large number of structurally related polypeptide
growth factors, each capable of regulating a fascinating
array of cellular processes including cell proliferation,
lineage determination, differentiation, motility, adhesion,
and death. Expressed in complex temporal and tissue-
specific patterns, TGF-b and related factors play a promi-
nent role in development, homeostasis, and repair of
virtually all tissues in organisms.1 For example, the
founding member of the TGF-b1 family was identified as a
regulator of mesenchymal growth and, separately, as an
antimitogen in epithelial cells.2,3 Activins were identified
as endocrine regulators of pituitary function and as induc-
ers of mesoderm in frogs.4,5 Bone morphogenic proteins
(BMPs) were identified as bone repair factors and, indepen-
dently, as dorsalizing agents in Drosophila.6,7 Nearly 30
members of the TGF-b family have been described in
human, and many TGF-b orthologs are known in mouse,
Xenopus and other vertebrates.1,6 Four are present in
Caenorhabditis elegans8 and seven in Drosophila melano-
gaster.9 The family is divided into two general branches,
the BMP/GDF (growth and differentiation factor) and the
TGF-b/activin/nodal branches, whose members have di-
verse, albeit often complementary effects. Additional mem-
bers, such as inhibin-a, act as ligand antagonists. Some
family members are expressed in a few cell types or for
limited periods of time during development, whereas
others are widespread during embryogenesis and in adult
tissues. AMH/MIS (antiMu¨llerian hormone or Mu¨llerian-
inhibiting substance) and GDF-8/myostatin are examples
of the former; TGF-b1 and BMP-4, of the latter10 (see the
reviews1,10–14 for the list of TGF-b family members, their
activities, and a detailed description of their signaling
mechanism). TGF-b1 to TGF-b3 are about 70% conserved
among themselves, whereas BMPs are about 60% identi-
cal. About 30% of the sequences of TGF-bs and BMPs are
identical, while inhibin-bB shares 30%, 40%, and ;27% of
its sequence with BMP-7, BMP-2, and the TGF-bs, respec-
tively. The decapentaplegic protein of Drosophila melano-
gaster, dpp, has 56%, 72%, 40%, and ;31% of its sequence
identical to BMP-7, BMP-2, inhibin-bB, and TGF-b, respec-
tively. Glial cell line–derived neurotrophic factor (GDNF)
and its subfamily members undergo similar modes of
dimerization as TGFs but have very little sequence similar-
ity (;14%) with members of the TGF-b family. Therefore,
the GDNF subfamily can be considered a member of the
broader cystine-knot superfamily (whose structural de-
tails are explained below), including nerve growth factor
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and platelet-derived growth factor, who members have
similar protomer structures but display different modes of
dimerization and share only ;15% of their sequence with
the TGF-b family.15,16
Members of the TGF-b family of growth factors are
synthesized as larger precursor molecules with an amino-
terminal signal sequence and a prodomain of varying size.
These precursor proteins are usually cleaved at a dibasic
or RXXR site to release a mature carboxy-terminal seg-
ment of 110 to 140 amino acids17 and are biologically
active as dimers. Members of the TGF-b family regulate
gene expression by bringing together two types of serine/
threonine kinase receptors,1,18 collectively known as the
TGF-b receptor family. Unlike other members of the
TGF-b family, GDNF family ligands activate intracellular
signaling cascades via the receptor tyrosine kinase Ret.19
The TGF-b receptor family is divided into two subfamilies,
type I receptors and type II receptors, on the basis of their
structural and functional properties. Type I receptors have
a higher level of sequence similarity than type II receptors,
particularly in the kinase domain.1 Type I and type II
receptors are glycoproteins of approximately 55 kDa and
70 kDa, respectively, with core polypeptides of 500 to 570
amino acids, including the signal sequence. Each receptor
contains an extracellular, or ecto-, domain; a short mem-
brane-spanning helix; and a cytoplasmic serine/threonine
kinase domain.20–24 Table I summarizes characteristics of
various TGF-b family ligands and their receptors, which
are identified biologically. Two general modes of ligand
binding have been observed: One mode involves direct
ligand binding (the biologically active form of TGF-b
ligands is a dimer of two monomers; henceforth, when a
ligand binding to a receptor is discussed, it is assumed that
the receptor or receptors is interacting with a ligand
dimer) to the ectodomain of the type II receptor and the
subsequent interaction of this complex with the type I
receptor. The type I receptor, in effect, becomes recruited
to the complex, a quality that is characteristic of TGF-b
and activin receptors. The second mode of binding is
typical of BMP receptors and is cooperative, involving type
I and type II receptor ectodomains that bind ligand with a
high affinity when expressed together but with a low
affinity when expressed separately.1 In the mechanisms
described above, type II receptors bind to ligand dimers,
subsequently (or simultaneously) recruit type I receptors,
and finally phosphorylate type I receptors at the GS
domain (containing a characteristic TTSGSGSG motif)
and thus activate them in transducing the signal to the
nucleus.
The TGF-b isoforms show remarkable structural homol-
ogy between themselves, including seven absolutely con-
served cysteine residues that form three intrachain disul-
fide bonds and one interchain disulfide bond. The TGF-b
and activins/inhibins contain an extra disulfide bridge
at the N-terminus of the molecule. The structures of
TGF-b2,25–26 TGF-b3,27 BMP-7/OP-1,28 BMP-2,29 and
GDNF30 were determined by X-ray crystallography, and a
model of TGF-b131 was calculated from NMR restraints.
The monomer is a thin, elongated, and slightly curved
molecule resembling an open left hand. As shown in Figure
Fig. 1. Ribbon representation of (a) BMP-2 ligand (PDB code: 3bmp)
and (b) ActR-II–ECD (PDB code: 1bte). Secondary structures are labeled.
Fingers are marked on the receptor structure. Figure was prepared using
MolScript.60
TABLE I. Interactions of TGF and Other Superfamily
Members With Their Receptors
Sequential binding
Ligand Type II receptor Type I receptor
TGF-b TbR2 ALK-1, ALK-2?, TbR-I, ALK-7
Activins AtR-II, AtR-II AtR-I, AtR-I
BMP-7 AtR2, AtR-II AtR-I
GDF-5 AtR-II, AtR-IIB AtR-I, AtR-IB
MIS/
AMH
AMHR AtR-I
Co-operative binding
Ligand Type II receptor Type I receptor
BMPs BR-2 BR-1A, BR-1B
dpp Punt Thick veins
(tkv)
Saxophone (sax)
GDF5 AtR-I, BR-1B
†Abbreviations include: TGF-b (transforming growth factor–b), BMP
(bone morphogenic protein), dpp (decapentaplegic), GDF (growth and
differentiation factor), ALK (Activin receptor-like kinases), MIS/AMH
(Mu¨llerian inhibiting substance/antiMu¨llerian hormone), TbR (trans-
forming growth factor receptor), AtR (activin receptor), and BR (bone
morphogenic protein receptor). This table was compiled according to
Massague,1 with a few corrections. Note that there is no species
specificity observed in ligand–receptor interactions.
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1(a), each monomer is folded into nine b-strands (b1–b9)
and a long a-helix (discussed below as a3). The fold can be
described as a hand with the “thumb” as the N-terminus
and the extended sheets as “fingertips” representing the
b2–b3 and b7–b8 loops. Accordingly, the convex surfaces
of the fingers correspond to the “knuckles” and the helix
region to the “wrist.” The residues exposed on the convex
surface involving b2, b3, b7, and b8 strands and loops
joining them define the “knuckle” epitope.33 All known
ligand sequences contain seven invariant Cys residues,
numbered as C2, C4, and C5 to C9; many of them contain
an extra pair of Cys residues, numbered as C1 and C3. The
structurally conserved region of the fold is described as a
cystine “knot” because cysteines C4, C5, C8, and C9
participate in an eight-membered macrocycle wide enough
for the last cystine bridge (formed by C3 and C7) to pass
through. The cysteines that form the N-terminal disulfide
bridge in the TGF-b are absent in other family members.
Because the proteins of this family lack a hydrophobic
core, the rigid cystine-knot scaffold is necessary for struc-
tural integrity. Further stabilization is achieved by dimer-
ization, which creates a hydrophobic core between the
protomers. In most cases such dimerization events are
accompanied by the formation of a disulfide bridge connect-
ing the two protomers at the C6 position.
The crystal structure of the extracellular domain of the
activin type IIA receptor (ActR-II–ECD) has also been
determined.32 The fold of the ActR-II–ECD comprised of
three antiparallel sheets formed by seven b-strands [Fig.
1(b)]. The molecule has both concave and convex surfaces,
which result from a curvature in the first b-sheet (b1–b2).
The ActR-II–ECD adopts a three-finger toxin fold, so
named because it is also observed in several toxins,
characterized by a common pattern of eight cysteines,
forming a conserved scaffold of four disulfide bridges. The
three fingers refer to three pairs of strands (b1–b2, b3–b4,
and b5–b6), which all point roughly in the same direction
[Fig. 1(b)]. ActR-II and cardiotoxin have the same disulfide
pattern (C1–C3, C2–C4, C5–C8, and C9–C10), with the
exception of an additional disulfide in ActR-II (C6–C7).
Among the type II receptors there is some variability in the
occurrence of cysteines. The majority of the extra cysteines
in other receptors are clustered in finger 1, which consti-
tutes the least conserved region, both sequence- and
lengthwise. TbR-I has four additional cysteines in finger 1
but lacks the two cysteines that constitute the C5–C8
disulfide bond in ActR-II. Punt has two extra cysteines in
finger 1.
The crystal structure of the human BMP-2 ligand in
complex with two high-affinity receptor Ia extracellular
domains (BR-Iaec) has been reported recently,
33 providing
important information on TGF–receptor interactions at
the molecular level. In this structure two molecules of the
type I receptor are bound to the ligand dimer in the wrist
epitope region of the ligand (additional details are de-
scribed in the Results and Discussion sections) mainly by
the hydrophobic surfaces of both molecules. This report
also confirmed that both type I and type II receptor
extracellular domains share the same fold, especially at
the central b-sheet, despite poor sequence identity. Differ-
ences at loop regions and insertions of noncore secondary
structures are evident; for example, a helix involved in
primary interactions with the ligand in the type I receptor
is absent in type II receptors.33 Instead, an additional
disulfide bridge, unique to type II receptors, links the
equivalent loop region at the convex surface to the central
b-sheet. This suggests that the two types of receptors have
different modes of binding to the ligand at the atomic level.
Only a limited number of functionally important resi-
dues have been identified in TGF-bs and in related growth
factors for binding the type II receptor. A study of the
influence of segment deletions, residue replacements, and
isoform chimeras on the binding affinity of TGF-bs for
their type II receptor (TbR-II) highlighted the importance
of C-terminal residues 83 to 112 of TGF-b1–3.34 The
structure–function analysis of activin-bA molecule is re-
ported here, and two amino acids involved in the binding of
the activin molecule to its type II receptor were identi-
fied35 on the knuckle epitope as important for binding,
Asp27 and Lys102.36 Through alanine scanning mutagen-
esis experiments on ActR-II–ECD, Gray et al. were able to
identify a cluster of hydrophobic residues (a hydrophobic
triad)—Phe42, Trp60, and Phe83—as critical for binding
to activins/inhibins.36 It is known that type II receptors
form a heteromeric complex with the ligand, but exactly
how many receptor molecules interact with the ligand is
not known.1 It is apparent from Table I that TGF-b ligands
can only bind to TbR-I and TbR-II, but no such specificity
is observed in the case of BMPs and activins. ActR-I binds
to activins/inhibins, BMP-7, and MIS/AMH; ActR-II binds
to activins, BMP-7, and GDF-5.1 This report suggested
that the determinants of ligand binding to receptors may
be conserved within the TGF-b subfamily and that the
determinants of specificity are different for the TGF-b and
activin/BMP subfamilies, whereas the residues that deter-
mine the specificity for activins and BMPs are similar.
Activin receptors bind to activins/inhibins, BMPs, MIS,
and GDF-5. Despite a remarkably similar structure, no
such binding was observed for the TGF-b ligands.
To determine the functionally important residues, we
compared the sequence distribution within the three fin-
gers of the receptor and the charge distribution of the
ligands, using the evolutionary trace (ET) method,37 first
applied by Litcharge et al. on SH2 and SH3 domains to
identify potential binding-site residues as targets for mu-
tagenesis in the TGF-b family of receptors. The five
available structures of TGF-b ligands (three TGFs and two
BMPs) and the three-dimensional models of dpp and
inhibin-bB, which were derived by comparative modeling,
were analyzed for differences in the distribution of polar
and hydrophobic residues on the surfaces of the molecules,
especially at the conserved residues38 important for bind-
ing the type II receptor. The extracellular domain of the
type II receptor was docked to the ligand-dimer type I
receptor complex. From the results of both previous mu-
tagenesis studies and of our analysis, the knuckle epitope
was identified as a site of interaction with the type II
receptor. Because the ligand molecules contain two sym-
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metric knuckle epitopes, two receptors can bind to the
ligand dimer, forming a tetrameric complex.
MATERIALS AND METHODS
Sequence Alignment and Clustering of Proteins
The 23 members of the TGF-b receptor2 family were
identified by a PSI-BLAST39 search using the ActR-IIA
ectodomain as a query sequence against the SWISS-PROT
Protein Sequence Database40 and used for evolutionary
analysis. The ectodomains of the sequences were aligned
using ClustalX41 (Version 1.8) and manually edited, ensur-
ing that gaps were not inserted into areas of known (or
predicted) secondary structures. A PHYLIP (Version 3.5)
distance matrix based on sequence dissimilarity indices
was generated and input into a KITSCH clustering pack-
age to build a rooted phylogenetic tree.42
Evolutionary Trace Analysis of Receptor
Sequences
An evolutionary trace is generated by comparing consen-
sus sequences for a group of proteins that originate from a
common node in a phylogenetic tree and are characterized
by a common evolutionary time cutoff (ETC) and then
classifying each residue as one of the three types: abso-
lutely conserved, class specific, or neutral. Here class
specific denotes residues occupying a strictly conserved
location in the sequence alignment but differing in the
nature of their conservation between various subgroups.
When structural and functional residues of a protein
family are not characterized, target residues can be chosen
for mutagenesis. This can also be mapped to known
protein structures to identify clusters of important amino
acids on the surface of the protein.
The ET analysis37 was performed using TraceSuite.8
First, the phylogenetic tree was split along evolutionary
time into five evenly distributed partitions: P01 to P05 in
order of increasing ETC. For each partition a trace proce-
dure was completed automatically in three steps: (1)
proteins connected by a common node with evolutionary
time greater than the given ETC were clustered together;
(2) a consensus sequence was generated for each group to
distinguish between conserved and nonconserved posi-
tions; and (3) a trace was generated by comparing the
consensus sequences of receptors. Residues were classified
into three types: absolutely conserved, class specific, or
neutral. All the receptor sequences considered for the
initial alignment were used for ET analysis. Punt se-
quence was not included because it is a lone element in the
evolutionary tree and may bias the results.
Comparative Modeling and Visualization
Mature carboxy terminus peptides of dpp of Drosophila
melanogaster and inhibin-bB of Homo sapiens were taken
from the SWISS-PROT databank.40 They were multiply
aligned using ClustalX41 to other members of the TGF-b
family. MODELLER43 (Version 4.0) was used to build
three-dimensional models of both proteins. BMP-2 [Pro-
tein Data Bank (PDB) code: 3bmp] was used as a template
for modeling dpp; BMP-2 (PDB code: 3bmp) and TGF-b3
(PDB code: 1tgj) were used as templates for modeling
inhibin-bB. MODELLER constructs minimized 3-D mod-
el(s) of a protein by the satisfaction of spatial restraints
extracted from the template PDB44 files. In each case 20
models of the query sequence were generated. The final
models were chosen on the basis of lowest energy and least
violation of structural restraints. The stereochemistry and
geometry of the models were assessed using PROCHECK45
(Version 3.4.4), which ensured that the models had more
than 85% residues in the core region of Ramachandran
plot. The models were energy-minimized with the
MAXIMIN2 option in SYBYL (Version 6.5, Tripos Associa-
tion, Inc.) using the TRIPOS force field. For every run of
energy minimization, 20 cycles of the Simplex method and
an additional 50 cycles of the Powell algorithm were
employed. The resulting models had no short contacts or
bad geometry. The dimer coordinates were generated
using a superposition program called SUPER (B. Neela,
personal communication). The punt (type II receptor for
the dpp molecule) receptor ectodomain was modeled using
the same procedure, with the ActR-II–ECD crystal struc-
ture (PDB code: 1bte) as template. The resulting models
and crystal structures were viewed by RASMOL, Version
2.6b2,46 and solvent-accessible surfaces and electrostatic
potentials were calculated and displayed using GRASP,
Version 1.1.47 Structure-based sequence alignment
of TGF-b ligands was compiled using the program
COMPARER, Version 2.0,48 and structure-annotated us-
ing JOY, Version 4.0.49,50
Docking Studies on Ligand Type II Receptor
Interactions
Global Range Molecular Matching GRAMM (Version
1.03) program51–53 uses an empirical approach to predict
the site of interaction between two molecules. Only the
atomic coordinates of the two molecules are required (no
information about the binding sites is needed). The pro-
gram performs an exhaustive six-dimensional search
through the relative translations and rotations of the
molecules.
The X-ray structures of the activin type II receptor (PDB
code: 1bte; solved at a resolution of 1.5 Å) and a complex of
BMP ligand dimer with its type I receptors (PDB code:
1es7; solved at a resolution of 2.90 Å) were docked using
GRAMM51–53 with a generic, hydrophobic mode and a grid
step of 2.1 Å. The program generated 1000 models to study
possible ways of the ligand–receptor interactions. The
models were examined for maximal hydrophobic interac-
tions and total interactions between the 1es7 and 1bte
structures using the distance cutoff value derived from
known cytokine-receptor crystal structures.
RESULTS AND DISCUSSION
Analysis of Receptor Type II Sequences
The aligned nonredundant sequences of receptor type II,
as shown in Figure 2, contain seven ActR-IIA sequences,
seven ActR-IIB sequences, four BR2 sequences, four TbR-II
sequences, and a punt receptor sequence from Drosophila
melanogaster. Sequences of subfamilies show high conser-
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vation among themselves, but across the subfamily there
is hardly any conservation apart from the cysteines.
Phe42, Trp45, Gly58, and Asn92 are characteristic of a
three-finger toxin fold and are largely conserved. However,
Phe42 is substituted by Tyr in ActR-IIB, BR2, and punt
but replaced by Val in TbR-II; Gly58, which is conserved in
ActR-IIB, BR2, and punt, is absent in TbR-II. In general,
the average sequence identity is around 25%. The punt
receptor shares 28% to 30% identity with BR2 and ActR-
IIB, 22% to 23% identity with ActR-IIA, and about 15%
identity with TbR-II. Trp45 and Asn92 are absolutely
conserved among all the type II receptor subtypes consid-
ered. An evolutionary tree was generated using the
PHYLIP package42 (Fig. 3). As expected, AtR and BR
sequences were found to be more similar and TbR se-
quence to stand on its own as a separate cluster.
Analysis of Residues in Fingers
Finger 1 contains loops of similar length that may be
important for specificity in binding to the ligand because
Fig. 2. Multiple alignment of 23 sequences of various type II receptor ectodomains with secondary
structures and fingers marked. ActR2A_MOUSE,* ActR2A_RAT, ActR2A_HUMAN, ActR2A_BOVIN,
ActR2A_SHEEP, ActR2A_GALLUS, and ActR2A_XENLA are activin type IIA receptors from mouse, rat,
human, bovine, sheep, chicken, and Xenopus. ActR2B_MOUSE, ActR2B_RAT, ActR2B_HUMAN,
ActR2B_BOVIN, ActR2B_GALLUS, ActR2B_ZEBRAFISH, and ActR2B_GOLDFISH are activin type IIB
receptors from mouse, rat, human, bovine, chicken, zebrafish, and goldfish. BMPR2_HUMAN, BMPR2_MOUSE,
BMPR2_GALLUS, and BMPR2_XENLA are bone morphogenic protein type II receptors from human, mouse,
chicken, and Xenopus. TGR2_HUMAN, TGR2_PIG, TGR2_MOUSE, and TGR2_RAT are transforming growth
factor type II receptors from human, pig, mouse, rat, and fruit fly. PUNT_DROSO is a homologue of activin type
II receptor in the fruit fly. ActR2A_MOUSE (PDB code: 1bte) is an activin type II receptor ectodomain sequence
from mouse with a known crystal structure.32 The sequence is shown in structure-based annotation using
JOY49,50. Please refer to the legend of Figure 6 for the JOY key.
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these loop regions display maximal sequence variation,
which was also confirmed by evolutionary trace method
(discussed later). Two negatively charged residues at the
tip of finger 1, Glu19 and Asp21 (ActR-IIA numbering) are
replaced by Asn and Leu in BR2 and by Ser and Cys in
TbR-II. Finger 1 of punt contains an extra disulfide bridge,
whereas that of TbR-II contains two extra disulfide bridges
(Fig. 1). This confirms what was found in previous model-
ing and scanning-deletion mutagenesis studies,54 that
residues in finger 1 (residues 58–60 and 63–65 of TbR-II),
facing the concave surface, are important for binding TGF.
Finger 2 contains very few residues in each receptor
sequence. However, punt, TbR-II, and BR2 receptors have
relatively longer finger2 region: two-residue insertion in
the case of TbR-II and punt and a one-residue insertion in
BR2. Residues 74–79 of finger 3 are exposed on the
concave surface; ActR-IIA has two positive and two nega-
tive charges in this loop, while ActR-IIB is predominately
negative. BR2 is polar and TbR-II is predominantly posi-
tive in this region, whereas punt contains one positive and
one negatively charged residue.
It has been reported that mutant receptors containing
deletions corresponding to loop regions of finger 1, the
b2–b3 loop, and finger 2 do not bind the ligand.54 However,
mutant receptors containing a deletion at finger 3, the loop
region before b1, the b4–b5 loop, and after b7 do bind the
ligand with affinities similar to those for wild-type recep-
tors.54 Because finger 2 is short, deletion of the loop
region corresponding to finger 2 might cause structural
changes to the receptor, rendering it unable to bind the
ligand. Thus, finger 2 may or may not be important for
binding. The highly variable finger 1 is not only a
potential binding interface but is also the second most
exposed conserved hydrophobic surface (as observed in
the crystal structure of ActR-II), which is present at the
convex side of the molecule. Finger 1 is a good candidate
both to provide a hydrophobic docking surface and to act
as a primary determinant of interaction and binding
specificity.32
Evolutionary Trace of Receptor II Sequences
The output from the TraceSuite program (which uses
the ET method37 and is by Innis et al.38) on the extracellu-
lar domain of TGF type II receptors is shown in Figure 4.
Analysis of the mapped traces for partitions P01 to P05
revealed clusters of potentially important residues on both
the concave and convex surfaces of the receptor structures.
The residues defined by the hydrophobic triad are at the
concave surface.36 In partition P01, apart from the struc-
turally invariant cysteines, Trp45, Val55, and Asn92 are
absolutely conserved among all receptor types considered
in the ET analysis. The conserved Val55 lies on b4 and is in
the vicinity of finger 2. Lys replaces Val55 in the punt
sequence. Other residues identified in partition P01 are
Thr8, Glu10, Asn15, Glu19, Glu29, Gly33, Ala43, Asn47,
Asp62, Asp63, Val81, Glu93, and Phe95. Gly33 and Ala43
are buried in the core and may have a structural role, and
Glu19 is on the b1–b2 loop (finger 1). Thr8, Glu10, Asn15,
Asn47, Glu93, and Phe95 do not face the concave surface
but are solvent accessible with no identified function. The
trace residues facing the concave surface are Glu29 (on
b2), Asp62 and Asp63 (on the b4–b5 loop), Val81 (on the
b–b6 loop; finger 3), and Phe83 (on b6; finger 3). No
class-specific residues were identified at P02.
Phe83 is in the hydrophobic triad, identified by alanine
scanning mutagenesis to be important for ligand bind-
ing.36 However, single mutations of Phe13, Phe14, Glu29,
and Asp62 do not alter binding specificity for activins and
inhibins.36 The ET method does not identify Phe13 (ex-
posed on the concave side) and Phe14 (exposed on the
convex side) as trace residues, for which the implication is
that these residues are probably involved in nonspecific
binding. The method, however, identifies Glu29 (at the end
of b1) and Asp62 (b4–b5 loop), which face away from the
three fingers [Fig. 1(b)]. Glu29 is replaced by Ser in both
TbR-II and BR2 and by Thr in punt; Asp62 is replaced by
Gly in BR2 and by Tyr in TbR-II, whereas the correspond-
ing residue in punt is deleted. This suggests that Glu29
and Asp62 might be playing a functional role in other
subfamilies not tested so far by mutagenesis experiments.
In the crystal structure of ActR-IIA,32 Thr44 (ActR-IIA
numbering), identified as a conserved residue at partition
P03 by ET analysis, is in the middle of a solvent-exposed
hydrophobic surface (Table II), created by Ala16, Phe42,
Fig. 3. Dendrogram containing 23 TGF-b families of type II receptor
ectodomains, selected, using PHYLIP3.5,42 on the basis of their se-
quence dissimilarity. The sequences are as described in the legend of
Figure 2.
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Val55, Trp60, Ile64, Val81, and Phe83 (recall that three of
these define the hydrophobic triad, important in ligand
binding36). Except for Ala16, all of these are trace resi-
dues. Ala16 is considered in the analysis as it is a
solvent-exposed hydrophobic residue and lies in a loop
region of finger 1. We refer to the hydrophobic triad as the
residues defining the principal hydrophobic patch, which
can be extended farther to include Ala16, Thr44, Val55,
Leu61, Ile64, and Val81, termed the “surrounding” hydro-
phobic patch. Thr44 is replaced by Leu in BR2 and by a Val
in TbR-II. Note that when there is a mutation of position
Lys56—which is spatially proximate to this extended
hydrophobic patch and is conserved in AtR, BR, and
punt—Ala does not display a drastic change in binding.36
Lys56 was not identified as a trace residue by our ET
analysis.
Structure-Based Analysis of TGF-b Ligands and
Identification of Determinants of Binding and
Specificity
Large exposed hydrophobic patches on a protein surface
often form part of the binding surface.55 In the human
growth hormone–receptor complex, a few hydrophobic
residues at the interface contribute the most to the free
energy of the interaction.56 The recently solved crystal
structure of the complex of the BMP-2–BRIA ectodo-
main,33 exemplifying TGF–TGF type I receptor interac-
tions, also demonstrates the same theme. Phe85 of BRIAec
helix a1 fits into a hydrophobic pocket of the ligand, where
it interacts with BMP-2’s Trp28 and Trp31, among other
residues. In the crystal structure of free BMP-2, this
pocket accommodates a 2-methylpentane-2,4-diol mole-
cule from the buffer solution and, in the case of TGF-b3, a
Fig. 4. Evolutionary Trace of type II receptor sequences (excluding punt) for partitions P01 to P05, aligned
with the amino acid sequences of AtR2A_mouse (activin receptor IIA from mouse), AtR2B_human (activin
receptor IIB from human), BR2_human (BMP receptor 2 from human), and TbR-II (TGFb type II receptor from
mouse). * indicates the residues are important for mutagenesis; n indicates solvent buried residues are as
shown in the crystal structure of AtR-II–ECD.32
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dioxane.27,29,33 The Ile62, Val63, and Leu66 of BMP-2
provide an almost exclusively hydrophobic surface, which,
together with Asn59, form the site of interaction with
Phe85 of the receptor molecule.30 In addition, Phe60,
Met78, and Ile99 of BRIA are central to the ligand-binding
interface.33 The residues correspond to Asn59, Ile62, Val63,
and Leu66 (BMP-2) in TGF-b ligands38 and to Phe85,
Phe60, Met78, and Ile99 (BRIA) in receptor 1 sequences,
which were identified as trace residues (unpublished re-
sults of authors). To identify the determinants of binding
and specificity for TGF–TGF type II receptors, the follow-
ing approaches were taken.
Structure of TGF Growth Factors and Analysis of
TGF-Like Sequences
The structures for TGF-b1–b3,25–27,31 BMP-7,28 and
BMP-229 when superposed in the best fit display an overall
root-mean-square deviation of less than 1.1 Å. However,
there are clear differences in some structural elements
between TGF-bs and BMPs; the N-terminus is not visible
in the crystal structure of BMP-229 and BMP-7.28 In
contrast, TGF-b1–3 exhibits a short N-terminal a-helix
(a1) that is anchored to the protein core by an additional
disulfide bridge.25–27,31 Moreover, BMP-2 and BMP-7 do
not contain the short helix a2 observed after the second
b-strand in TGF-bs and is replaced by a tighter nonhelical
turn. This feature is conserved among known BMPs,
GDFs, activins, and other subfamilies. However, the struc-
tures of BMP-2 and BMP-7 show a unique conformation at
the loop preceding a3: a longer loop with a three-residue
insertion (a short b-strand in BMP-2).
Analysis of surface residues of ligand molecules for
difference in charge distribution
Figure 5 shows the GRASP surface representation47 of
structures of TGF-b1–3, BMP-2, and BMP-7 and models of
inhibin-bB and dpp. Large hydrophobic areas are concen-
trated, especially on the wrist and knuckle epitope regions
of the ligand dimers. It is clear from the figure that the
charge distribution is different between TGF-b isoforms
and the activin subfamily of proteins, especially in the
knuckle epitope and in the loops of the b2–b3 and b7–b8
strands. These regions have a high negative charge in
BMPs, inhibins, and dpp, whereas they are positively
charged in TGF-bs (the conservation is confirmed using
multiple sequence alignment of ligands). Unlike BMPs,
dpp is in general polar at the b7–b8 loop, at the knuckle
epitope, where Asp93, Glu95, and Lys96 of BMP-2 are
replaced in dpp by Asn, Gln, and Thr, respectively. This
difference in charge distribution together with the struc-
tural differences discussed before can be instrumental in
giving rise to specificity while binding to receptors. In
Fig. 5. Electrostatic potential representation of the known and modeled structures of the TGF-b family of ligands using GRASP.47 Red surface
patches indicate acidic residues, and blue patches indicate basic residues. The structures are (a) bone morphogenic protein 2, (b) inhibin-bB, (c) bone
morphogenic protein 7, (d) decapentaplegic protein (e) transforming growth factor–b1, (f) transforming growth factor–b2, and (g) transforming growth
factor–b3. The charged residues are marked, and the numbering is according to the structural positions given in PDB files. The hydrophobic residues are
marked for dpp.
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addition, all the structures have a positive charge at the
N-terminus (conserved positively charged residue, two
residues after C2), which accounts for their heparin bind-
ing.57 However, in BMPs the N-terminus might fold back
to shield this charge (as observed in the case of the
inhibin-bB model), and TGF-bs are less positive than
BMPs in this region.
Evolutionary Trace of Ligands and Identification of
Residues Implicated in Binding and Specificity
Through applying the ET method to multiply aligned
sequences of the TGF-b superfamily of ligands, Innis et
al.38 were able to identify trace residues. Trp28 and Trp31
of BMP-2, which have primary interactions with Phe85 of
BRIAec (see above), were found to be absolutely conserved
in the TGF-b family alignment and were identified as trace
residues.38 The mutation of Trp31 to alanine significantly
decreases the stability of the BMP-2–BRIAec complex.
33
Interestingly, neither Trp28 nor Trp31 is conserved in
distant relatives like GDNF.
Here we will discuss those trace residues that occur on
the knuckle epitope (important for receptor binding), are
topologically equivalent (using COMPARER48), and dis-
play similar characteristics (identified by JOY49,50; Fig. 6).
Two interesting clusters of residues were identified: first,
at alignment positions 35, 36, 37, 92, 93, 94, 96, 98, 104,
105, and 106 (Fig. 6; residues forming the knuckle epitope).
For BMP-2 (PDB code: 3bmp), these residues are Val33,
Ala34, Pro35, Ala86, Ile87, Ser88, Leu90, Leu92, Val98,
Val99, and Leu100. A second small cluster of residues, at
alignment positions 17, 18, 43, and 115 (Arg16, His17,
Phe41, and Glu109, according to BMP-2 numbering), is
Fig. 6. Structure-based sequence alignment of the TGF-b family using COMPARER48; it was compiled
using JOY.49,50 Solvent-accessible and solvent-inaccessible residues are shown in upper case letters and
lower case letters, respectively. Residues in positive phi are indicated in italics; residues with cis peptide in the
backbone or that have disulfide bonds are indicated by the presence of a breve (s˘) or a cedilla (c¸), respectively.
Hydrogen bonds formed to the side chains, main chain amides, and main chain carbonyls of the other residues
are indicated by the presence of a tilde (˜) on top, by boldface, and by underlining, respectively. The secondary
structures are marked and numbered.
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rather surprising. However, note that the N-terminus of
the BMP family of ligands, not seen in the crystal struc-
ture, could fold back in this region, attributing a structural
rather than a functional role to these residues. The trace
residues at the knuckle epitope are divided into two
classes [Table III(a,b)]: (1) the residues implicated for
ligand binding and (2) the residues implicated for binding
as well as specificity, most of which are subfamily-specific
and class-specific residues. The first cluster could be the
preferred site of interaction with hydrophobic clusters on a
type II receptor, as identified by mutagenesis studies and
in this study. Residue Pro35 is absolutely conserved in all
the ligand sequences considered for our analysis but is
absent in GDNF. Val33 and Ala34 are replaced by charged
residues in TGF-b isoforms, whereas Leu100 is replaced
by a charged residue in inhibins; other residues in cluster
1 are conserved substitutions. In cluster 2 in TGF-bs
Arg16 is replaced by a hydrophobic residue. Alignment
position 18 (Fig. 6; His17 of BMP-2) is occupied by a
positively charged residue in all the known sequences.
Phe41, adopting unusual f/c angles (67°, 178°) in the
Ramachandran plot58–59 although not in the dimer inter-
face, forms interchain contact at the backbone carbonyl
with the neighboring subunit in BMP-2, and its side chain
is solvent-exposed29 on the knuckle epitope. This residue
is present where the b-strands b2, b5, b 6, and b9 are
arranged close enough to form a short segment of the
four-stranded antiparallel b-sheet, as evident in the crys-
tal structure.29 This arrangement is also observed in all
known proteins in the TGF-b superfamily. As shown in
Table III, Glu109 (BMP-2 numbering) is specific for BMP-2
and inhibin subfamilies, which is a positively charged
residue (Arg/Lys) in TGF-bs and BMP-7 and a valine in
dpp. Such differences of trace residues point to class-
specific electrostatic distribution and receptor specificity.
Given the above results and the crystal structure of
BMP-2 with its type I receptor, it is plausible that finger 1
(with loop region of b2–b3) of the type II receptor interacts
TABLE II. Residues of Receptor Type II Important for Interaction with Ligands That Were Identified Using ET Method
Position
Principal patch Surrounding patch
91 111 146 58 93 106 116 119 139
AtR-IIA F42 W60 F83 A16 T44 V55 L61 I64 V81
AtR-IIB Y42 W60 F84 A16 S44 V55 L61 F64 V81
BR-2 Y41 W59 F89 P13 L43 V54 I62 P65 I82
TbR-II V85 H102 M135 V56 V87 V100 T108 G110 G130
Punt Y37 F57 F81 E10 L39 K52 T58 M60 G77
TABLE III(A). Specific Residues Implicated for High-Affinity Binding
Position 21 23 25 37 43 94 96 98
Tgfb-III Y21 D23 R25 P36 N42 T87 L89 Y91
Tgfb-II Y21 D23 K25 P36 N42 T87 L89 Y91
Tgfb-I Y21 D23 R25 P36 N37 P87 V89 Y91
BMP-2 Y20 D22 S24 P35 F41 S88 L90 L92
BMP-7 Y44 S46 R48 P59 Y65 S113 L115 F117
dpp Y9 D11 S13 P24 Y30 A78 L80 L82
IHB B F17 D19 R21 P32 N39 S89 L91 F93
TABLE III(B). Subfamily-Specific Residues Implicated for Receptor Specificity and Binding
Position 17 18 32 35 36 92 93 104
Tgfb-III V17 R18 K31 H34 E35 P85 L86 P96
Tgfb-II L17 R18 K31 H34 E35 P85 L86 P96
Tgfb-I V17 R18 K31 H34 E35 P85 L86 P96
BMP-2 R16 H17 D30 V33 A34 A86 I87 V98
BMP-7 K40 H41 D54 I57 A58 A111 I112 V123
dpp R5 H6 D19 V22 A23 S76 V77 V88
IHB B R13 Q14 D27 I30 A31 T87 M88 I99
Position 105 106 107 108 115
TGF-b3 K97 V98 E99 Q100 K107
TGF-b2 K97 I98 E99 Q100 K107
TGF-b1 K97 V98 E99 Q100 R107
BMP-2 V99 L100 K101 N102 E109
BMP-7 I124 L125 K126 K127 R134
dpp V89 L90 K91 N92 V99
IHB B V100 K101 R102 D103 E110
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with the knuckle epitope of the ligand if the C-termini of
both type I and type II receptors need to point roughly in
the same direction and the type II receptor interacts with
the ligand at its concave surface32,33,54 with the hydropho-
bic triad residues. The finger 3 loop region of the type II
receptor does not play an important role in binding. Some
residues identified by the ET method in the surrounding
patch of receptor type II are also reported in the deletion
studies of the core region (53–55, 83–85, 98–100, and
143–145, TbR-II numbering; see Table II) of TbR-II.54
Thus, the ET method can be used both to rationalize the
result of the mutagenesis studies and to predict the targets
for the mutagenesis.
Docking Studies of the Type II Receptor to the
Ligand–Dimer Type I Complex
The nature of interactions at the ligand type I receptor
binding site was primarily hydrophobic.33 The above anal-
yses of the trace residues of solvent-exposed hydrophobics
and the overall similarities between type I and type II
receptors suggest similar hydrophobic interactions in TGF
ligand type II receptor binding [Fig. 7(a,b)]. One thousand
Fig. 7. Predicted mode of interaction between transforming growth factor and type II receptor. (a) Structure of BMP dimer in GRASP surface
representation.47 Key residues were identified by the evolutionary trace (ET) method37; those that are probably important for binding (principal patch) are
denoted in cyan. Additional residues (surrounding patch), also identified by the ET method, are shown in magenta. (b) Same as (a) except for the
extracellular domain of the activin type II receptor. Regions corresponding to finger 1, finger 2, and finger 3 (also see Fig. 1) are denoted with yellow,
green, and violet arrows. The proposed complimentary areas of interaction in the ligand dimer are marked in similar colors in (a). (c) Distribution of the
total number of hydrophobic contacts for 1000 models of the interaction between the type II receptor (PDB code: 1bte) and ligand dimer complexed with
two type I receptor molecules (PDB code: 1es7). Hydrophobic contacts on the type II receptor were measured between the two molecules as the number
of CaOCa distances of hydrophobic residues of 1es7 within 12 Å. Inset to Figure 7(c) models with high hydrophobic contacts (seven or more) at the
principal patch of the type II receptor were examined for additional hydrophobic interactions, including the surrounding hydrophobic patch. (d) Ribbon
representation of one of the models of the interaction between a type II receptor and a type I receptor-bound ligand dimer. This model, suggested by
GRAMM, has a high number of hydrophobic residues at the predicted binding site [Fig. 7(c)]. Activin type II receptors are shown in cyan, BMP dimer in
magenta, and the two type I receptors in gray. The knuckle epitope of the ligand dimer and finger 1 and finger 3 of the type II receptor (denoted by yellow
and violet arrows) were predicted to be the key regions for forming the binding interface. This picture was prepared using SETOR.61
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GRAMM51–53 models of the type II receptor interacting
with the ligand dimer complexed with two type I receptors
were generated. The models were examined for maximal
hydrophobic interactions (defined as interaction between
the hydrophobic residues of both structures) and total
interactions (defined as interaction between all the resi-
dues of both structures) using the Ca distance cutoff of 12
Å to define interacting pairs. Figure 7(c) shows the distri-
bution of the number of models with the number of
hydrophobic interactions between the ligand type I recep-
tor complex and receptor type II. Models with an appre-
ciable number of hydrophobic interactions at the principal
patch (data not shown) were specifically examined after
including the surrounding hydrophobic patch residues
[Fig. 7(c), inset]. Interestingly, models with the highest
number of hydrophobic interactions [Fig. 7(c)] and of total
interactions [as shown in Fig. 7(d)] with key residues of the
type II receptor closely correspond to the ET results,
suggesting a theme involving the knuckle epitope at the
ligand as the receptor-binding site.
CONCLUSIONS
We have identified the clusters of residues that lie on the
knuckle epitope of ligand molecules and the concave
surface of type II receptor molecules, which may play an
important role in complex formation. These clusters are
hydrophobic patches surrounded by charged residues on
the surface of molecules. We propose that finger 1 and a
part of finger 2 of the type II receptor, with the central
hydrophobic patch, interact with the knuckle epitope of
the ligand (mainly the convex side on b2–b 3, b7–b8, and
the loop regions joining them) as they provide the large
conserved hydrophobic surface for docking. The b2–b3 loop
region may be interacting with the smaller cluster identi-
fied using the ET method, which shows good agreement
with GRAMM docking studies. Although each type I
receptor interacts simultaneously with both ligand pro-
tomers at the wrist epitope,33 we predict that the type II
receptor interactions are with one protomer each at the
knuckle epitope. These predictions are supported by dele-
tion studies on ligands,31,34,35 deletion and mutagenesis
studies on receptor type II sequences,36,54 and the orienta-
tion of receptor type I in the crystal structure in complex
with BMP-2.33 We have discussed the important amino
acids that can be targets for future mutagenesis studies. It
will also be interesting to prepare TGF chimeras of the
loop region between the b2–b3 loop and the b7–b8 loop
because the difference in charge distribution in this region
may contribute to specificity in the identification of recep-
tors. Various tools, such as the study of evolutionary trees,
conserved residues of the aligned sequences, spatial posi-
tions of interesting residues, charge distribution on their
three-dimensional fold, and docking studies, have been
used to provide structural explanations for ligand–
receptor specificity, which have general value for analyz-
ing protein–protein interactions.
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